TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34153324

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (HIIC)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Exercise (MICC)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (HIIR)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Exercise (MICR)
Number of subjects: 16
Study: 35144203

Group type: EXPERIMENTAL
Intervention: Ethics laboratory program (8 weeks, interactive education methods including ethical scenarios, case studies, roleplay, group discussions, project papers, and watching movies)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ethics laboratory program (8 weeks, interactive education methods)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard fundamentals of nursing curriculum (control group)
Number of subjects: 100
Study: 33818600

Group type: EXPERIMENTAL
Intervention: 10-kHz spinal cord stimulation (SCS) plus conventional medical management (CMM)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Conventional medical management (CMM)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: 10-kHz SCS plus CMM
Number of subjects: 216

Group type: COMPARATOR
Intervention: CMM
Number of subjects: 216
Study: 36315226

Group type: EXPERIMENTAL
Intervention: Bioptron light therapy for 12 minutes three times per week plus standard wound care
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard wound care only
Number of subjects: 40
Study: 32533228

Group type: EXPERIMENTAL
Intervention: Radiochemotherapy plus cetuximab (arm A)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Radiochemotherapy (arm B)
Number of subjects: 74
Study: 36240610

Group type: EXPERIMENTAL
Intervention: Standard dose of GH (SG), mean baseline GH dose of 0.13 mg/day increased to 0.31 mg/day at study end
Number of subjects: 18

Group type: COMPARATOR
Intervention: Very low fixed dose of GH (LG), 0.1 mg/day
Number of subjects: 18

Group type: COMPARATOR
Intervention: Very low fixed dose of GH (LG)
Number of subjects: 18
Study: 34399063

Group type: EXPERIMENTAL
Intervention: Combined soy and hop extract (n=38)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo (n=40)
Number of subjects: 78
Study: 616850292

Group type: EXPERIMENTAL
Intervention: Air powder abrasive system (AF)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Rubber cup with pumice powder (RC)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 9
Study: 35137287

Group type: EXPERIMENTAL
Intervention: SG?+?RF
Number of subjects: 278

Group type: COMPARATOR
Intervention: SG
Number of subjects: 278
Study: 34120150

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 98

Group type: COMPARATOR
Intervention: Glibenclamide 5 mg/day
Number of subjects: 98
Study: 35763588

Group type: EXPERIMENTAL
Intervention: ACCEL-2 group
Number of subjects: 25

Group type: COMPARATOR
Intervention: ACCEL-1 group
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 25
Study: 34707496

Group type: EXPERIMENTAL
Intervention: Ejiao (6 g/day)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 35373729

Group type: EXPERIMENTAL
Intervention: Standardized mate extract
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32665197

Group type: EXPERIMENTAL
Intervention: Sutureless circumcision (Group 1)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Interrupted sutures (Group 2)
Number of subjects: 182
Study: 36106379

Group type: EXPERIMENTAL
Intervention: Adjunctive perampanel (≤8 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32653580

Group type: EXPERIMENTAL
Intervention: Dual-task gait and balance training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Single-task gait and balance training
Number of subjects: 20
Study: 34989808

Group type: EXPERIMENTAL
Intervention: Insomnia Disorder
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Perinatal Sleep Disruption
Number of subjects: 163

Group type: COMPARATOR
Intervention: Low Complaint
Number of subjects: 163
Study: 33411545

Group type: EXPERIMENTAL
Intervention: Self‐Reflection Resilience Training (SRT; n = 96)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control group (n = 108)
Number of subjects: 204
Study: 32775442

Group type: EXPERIMENTAL
Intervention: Modern contraceptive methods
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Age ≥ 35 years
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Able to read and write
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Primary school education
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Secondary school education
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Counseled on contraceptive methods
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Moderate knowledge on modern contraceptive method
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Good knowledge on modern contraceptive method
Number of subjects: 580
Study: 35317611

Group type: EXPERIMENTAL
Intervention: Priming iTBS
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Nonpriming iTBS
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Mirror visual feedback
Number of subjects: 42
Study: 32320172

Group type: EXPERIMENTAL
Intervention: ABA intervention (assets-based approach with behaviour change techniques)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Qualitative data from women, infant-feeding helpers, and maternity services
Number of subjects: 103

Group type: COMPARATOR
Intervention: N/A (usual care)
Number of subjects: 103
Study: 33261505

Group type: EXPERIMENTAL
Intervention: 125I particle‐integrated esophageal covered stent and hyperbaric oxygen
Number of subjects: 45

Group type: COMPARATOR
Intervention: 125I particle‐integrated esophageal covered stent
Number of subjects: 45
Study: 35575780

Group type: EXPERIMENTAL
Intervention: CDS software
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (standard medication workflow)
Number of subjects: 40
Study: 33847634

Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) and methylene blue (MB) combination method
Number of subjects: 415

Group type: COMPARATOR
Intervention: Methylene blue (MB) method alone
Number of subjects: 415
Study: 34412906

Group type: EXPERIMENTAL
Intervention: Pictograms on prescription medication labels
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Pictograms for dose and route of administration, and dosage frequency
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Assessed pictograms
Number of subjects: 250
Study: 32499018

Group type: EXPERIMENTAL
Intervention: Conscious Sedation (CS)
Number of subjects: 120080

Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 120080
Study: 35649964

Group type: EXPERIMENTAL
Intervention: Ankle arthrodesis combined with mosaic bone autograft transplantation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ankle arthrodesis (control group)
Number of subjects: 20
Study: 34650034

Group type: EXPERIMENTAL
Intervention: Toripalimab plus carboplatin and pemetrexed administered every three weeks for up to six cycles, followed by maintenance of toripalimab and pemetrexed.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Toripalimab plus chemotherapy (carboplatin and pemetrexed)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Biomarker analysis
Number of subjects: 40
Study: 32135135

Group type: EXPERIMENTAL
Intervention: Gestational diabetes
Number of subjects: 2458

Group type: EXPERIMENTAL
Intervention: Glucose levels at weeks 10-14
Number of subjects: 2458
Study: 36328209

Group type: EXPERIMENTAL
Intervention: EUS-guided gallbladder drainage (EUS-GBD) after SEMS placement
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional biliary drainage alone (Control)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: EUS-guided gallbladder drainage (EUS-GBD)
Number of subjects: 44
Study: 33569770

Group type: EXPERIMENTAL
Intervention: Azithromycin treatment for 48 weeks
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 142
Study: 32713702

Group type: COMPARATOR
Intervention: Low Grass Hay (LGH) - 10% GH
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Medium Grass Hay (MGH) - 17.5% GH
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: High Grass Hay (HGH) - 25% GH
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All treatments (LGH, MGH, HGH)
Number of subjects: 45
Study: 35446178

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 12
Study: 32942949

Group type: EXPERIMENTAL
Intervention: Qigong exercise
Number of subjects: 15
Study: 32367657

Group type: EXPERIMENTAL
Intervention: CT perfusion (CTP) performed in 2018 (post-DAWN trial)
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: CT perfusion (CTP) in late presenters in 2018 (post-DAWN trial)
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: CT perfusion (CTP) sensitivity, specificity, and proportions of CTP with a final diagnosis of acute stroke, TIA or non-stroke
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: CT perfusion (CTP) utilization in 2018 (post-DAWN trial)
Number of subjects: 443
Study: 35216560

Group type: EXPERIMENTAL
Intervention: Independent Medical Evaluation (IME)
Number of subjects: 5888

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 5888
Study: 35114159

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin with chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 34257640

Group type: EXPERIMENTAL
Intervention: Real tDCS
Number of subjects: 47

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 47
Study: 35332062

Group type: EXPERIMENTAL
Intervention: Dostarlimab + Niraparib (Part A)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Dostarlimab + Carboplatin-Paclitaxel (Part B)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Dostarlimab + Niraparib + Bevacizumab (Part C)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Dostarlimab + Carboplatin-Paclitaxel + Bevacizumab (Part D)
Number of subjects: 55
Study: 34810368

Group type: EXPERIMENTAL
Intervention: Wax
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Polyvinyl siloxane
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Polyether
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison between wax and polyvinyl siloxane
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison between wax and polyether
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison between polyvinyl siloxane and polyether
Number of subjects: 30
Study: 32310283

Group type: EXPERIMENTAL
Intervention: Management by alternative care practitioners (ACPs)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Adherent patients to PAP therapy
Number of subjects: 156
Study: 34864978

Group type: EXPERIMENTAL
Intervention: Ultraslow thrombolytic regimen (25 mg of rtPA infused in 25 hours)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Fast thrombolytic regimen (50 mg of rtPA infused in 6 hours)
Number of subjects: 120
Study: 33446305

Group type: EXPERIMENTAL
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 5310

Group type: EXPERIMENTAL
Intervention: SAVR in patients with severe coronary artery disease (SevCAD)
Number of subjects: 5310

Group type: EXPERIMENTAL
Intervention: SAVR in patients with concomitant ascending aorta replacement (CAAR)
Number of subjects: 5310

Group type: EXPERIMENTAL
Intervention: SAVR in patients with non-tricuspid aortic valve (NTAV)
Number of subjects: 5310

Group type: EXPERIMENTAL
Intervention: SAVR in patients with concomitant mitral/tricuspid valve (CMTV)
Number of subjects: 5310
Study: 35487945

Group type: EXPERIMENTAL
Intervention: Viewing a trauma film (COVID-19 related footage)
Number of subjects: 70
Study: 32917529

Group type: EXPERIMENTAL
Intervention: FOLFIRI plus cetuximab
Number of subjects: 592

Group type: COMPARATOR
Intervention: FOLFIRI plus bevacizumab
Number of subjects: 592
Study: 36318424

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Adherence and Depression (CBT-AD)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Enhanced Treatment as Usual (ETAU)
Number of subjects: 143
Study: 34162831

Group type: EXPERIMENTAL
Intervention: Clinical-stage orally administered drugs targeting inhibitor of apoptosis proteins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Primary human liver organoid models
Number of subjects: 0
Study: 36321647

Group type: EXPERIMENTAL
Intervention: Calcipotriol‐Betamethasone Dipropionate (Cal/BD) foam alone
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Calcipotriol‐Betamethasone Dipropionate (Cal/BD) foam with Ablative Fractional Laser (AFL) treatment
Number of subjects: 11

Group type: COMPARATOR
Intervention: Calcipotriol‐Betamethasone Dipropionate (Cal/BD) foam
Number of subjects: 11
Study: 33649444

Group type: EXPERIMENTAL
Intervention: Journal provided
Number of subjects: 100

Group type: COMPARATOR
Intervention: No journal (control group)
Number of subjects: 100
Study: 32138709

Group type: EXPERIMENTAL
Intervention: Propranolol treatment in children with long-QT syndrome
Number of subjects: 51

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Standing test with a cut-off of 440 ms
Number of subjects: 51
Study: 33845856

Group type: EXPERIMENTAL
Intervention: EYE‐2 intervention + standardised EIP service
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standardised EIP service alone
Number of subjects: 0
Study: 83012907

Group type: EXPERIMENTAL
Intervention: Propoxyphene napsylate (PN) 800 mg in two divided doses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methadone 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methadone 20 mg
Number of subjects: 0
Study: 34431926

Group type: EXPERIMENTAL
Intervention: Slow injection technique without aspiration
Number of subjects: 148

Group type: COMPARATOR
Intervention: Slow injection with aspiration
Number of subjects: 148
Study: 32331042

Group type: EXPERIMENTAL
Intervention: Lumateperone 42mg
Number of subjects: 1073

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 1073

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1073
Study: 33745625

Group type: EXPERIMENTAL
Intervention: High Protein group (1.6 g of protein/kg/day)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Low Protein group (0.8 g of protein/kg/day)
Number of subjects: 45
Study: 35346353

Group type: EXPERIMENTAL
Intervention: Resistance exercise program (60 min, once a week for 12 weeks, and self-exercise twice a week)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Resistance exercise program
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study: 32592215

Group type: EXPERIMENTAL
Intervention: Cryotherapy protocol with 1 cycle (10 seconds freezing and thawing)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cryotherapy protocol with 2 cycles (10 seconds freezing and thawing)
Number of subjects: 48
Study: 37587796

Group type: EXPERIMENTAL
Intervention: Neutral-pressure needleless connectors (NCs)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Negative-pressure needleless connectors (NCs)
Number of subjects: 201
Study: 34900891

Group type: EXPERIMENTAL
Intervention: Extended maintenance intervention delivered individually by an intervention coordinator
Number of subjects: 1038

Group type: COMPARATOR
Intervention: Standard maintenance intervention
Number of subjects: 1038
Study: 32267771

Group type: EXPERIMENTAL
Intervention: Multiple interventions within four treatment domains: antibiotics, antiviral therapy for influenza, host immunomodulation with extended macrolide therapy, and alternative corticosteroid regimens.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ventilatory and oxygenation strategies.
Number of subjects: 0
Study: 34283019

Group type: EXPERIMENTAL
Intervention: solriamfetol 37.5 mg (OSA only)
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: solriamfetol 75 mg
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: solriamfetol 150 mg
Number of subjects: 710

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 710
Study: 34981165

Group type: EXPERIMENTAL
Intervention: [18F]FDG‐PET/CT‐driven group
Number of subjects: 132

Group type: COMPARATOR
Intervention: Diagnostic surgery group
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: [18F]FDG‐PET/CT‐driven management
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: [18F]FDG‐PET/CT for non‐Hürthle cell nodules
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: [18F]FDG‐PET/CT for Hürthle cell nodules
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: [18F]FDG‐PET/CT
Number of subjects: 132
Study: 33301018

Group type: EXPERIMENTAL
Intervention: Inpatients receiving invasive mechanical ventilation (5625 patients, 15.9%)
Number of subjects: 64781

Group type: EXPERIMENTAL
Intervention: Inpatients admitted to ICU (6849 patients, 19.4%)
Number of subjects: 64781

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 64781

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 64781

Group type: EXPERIMENTAL
Intervention: Calcium channel blockers
Number of subjects: 64781

Group type: EXPERIMENTAL
Intervention: Patients with both azithromycin and hydroxychloroquine
Number of subjects: 64781
Study: 35018575

Group type: EXPERIMENTAL
Intervention: Eccentric contraction
Number of subjects: 18

Group type: COMPARATOR
Intervention: Concentric contraction
Number of subjects: 18
Study: 33081982

Group type: EXPERIMENTAL
Intervention: Vegan meal (V-meal)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional meat meal (M-meal)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both meals
Number of subjects: 60
Study: 36058514

Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) intervention with ten home visits over one year
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) intervention
Number of subjects: 223

Group type: COMPARATOR
Intervention: Certified Asthma Educator (AE-C) intervention with two clinic sessions over one year
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Both CHW and AE-C interventions
Number of subjects: 223
Study: 33882392

Group type: EXPERIMENTAL
Intervention: Qualitative interviews exploring decision-making experiences in TPTL
Number of subjects: 10
Study: 34881655

Group type: EXPERIMENTAL
Intervention: Evaluation of women categorized as professional
Number of subjects: 201

Group type: COMPARATOR
Intervention: Evaluation of women categorized as sexy
Number of subjects: 201
Study: 34342205

Group type: EXPERIMENTAL
Intervention: Minimal dissection group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional surgery group
Number of subjects: 30
Study: 32430078

Group type: EXPERIMENTAL
Intervention: Supervised exercise program (bi-weekly) including aerobic training, strengthening, and cardiovascular exercises for 8 weeks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care/no intervention (control group).
Number of subjects: 0
Study: 34737064

Group type: EXPERIMENTAL
Intervention: Sprifermin (recombinant FGF18), administered intra-articularly over a 2-year period.
Number of subjects: 284

Group type: COMPARATOR
Intervention: Placebo, administered intra-articularly over a 2-year period.
Number of subjects: 284

Group type: COMPARATOR
Intervention: Sprifermin vs Placebo in low PRO-C2 group.
Number of subjects: 284

Group type: COMPARATOR
Intervention: Sprifermin vs Placebo in high PRO-C2 group.
Number of subjects: 284
Study: 33281083

Group type: EXPERIMENTAL
Intervention: Hyaluronidase 2.5 units
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hyaluronidase 5 units
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hyaluronidase 10 units
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hyaluronidase 20 units
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (no hyaluronidase)
Number of subjects: 9
Study: 34091813

Group type: EXPERIMENTAL
Intervention: Sublingual dexamethasone 8 mg (2 ml) with normal saline administered 1 hour before surgery
Number of subjects: 150

Group type: COMPARATOR
Intervention: Intramuscular dexamethasone 8 mg (2 ml) administered 1 hour before surgery
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Sublingual dexamethasone 8 mg
Number of subjects: 150

Group type: COMPARATOR
Intervention: Intramuscular dexamethasone 8 mg
Number of subjects: 150
Study: 35023094

Group type: EXPERIMENTAL
Intervention: 8-week stress management program including stress- and diet-related psychoeducation, diaphragmatic breathing, guided imagery, progressive muscle relaxation, and cognitive reconstruction.
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 8-week stress management program
Number of subjects: 53

Group type: COMPARATOR
Intervention: Type of surgery (partial or total mastectomy)
Number of subjects: 53
Study: 35197354

Group type: EXPERIMENTAL
Intervention: 800 mg vaginal micronised progesterone supplemented with 50 mg intramuscular progesterone per day
Number of subjects: 824

Group type: COMPARATOR
Intervention: 800 mg vaginal micronised progesterone
Number of subjects: 824
Study: 34526921

Group type: EXPERIMENTAL
Intervention: Total Sleep Deprivation (TSD) followed by Bright Light Therapy (BLT) (10,000 lux, 30 min/day) as add-on to standard treatment
Number of subjects: 33

Group type: COMPARATOR
Intervention: Short sleep-hygiene consultation as add-on to standard treatment
Number of subjects: 33
Study: 32548915

Group type: EXPERIMENTAL
Intervention: FXIIIa on Day 2 after MI
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: FXIIIa levels
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: FXIIIa levels after 12 months
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: FXIIIa activity
Number of subjects: 146
Study: 35272334

Group type: EXPERIMENTAL
Intervention: Methenamine with cranberry capsules
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo (cranberry alone)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 182
Study: 32868176

Group type: EXPERIMENTAL
Intervention: Oxytocin (24 IU)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 35944747

Group type: EXPERIMENTAL
Intervention: In-center supervised exercise training incorporating majority aerobic but also muscle strengthening activities
Number of subjects: 99

Group type: COMPARATOR
Intervention: Group health education control intervention
Number of subjects: 99
Study: 33338464

Group type: EXPERIMENTAL
Intervention: Early intra-aortic balloon pump (IABP) implantation
Number of subjects: 200

Group type: COMPARATOR
Intervention: Vasoactive treatments
Number of subjects: 200